Gottlieb: Gene Therapies Could Transform Health Care, If Payers Cover

Former FDA Commissioner Scott Gottlieb named payer tactics as one of the biggest obstacles facing the gene therapy space, as novel drugs seeking coverage after receiving FDA approval are often viewed by payers as not having enough data on which to base a coverage decision. During a live interview hosted by the Washington Post on June 11, Gottlieb argued that payers are using FDA’s regulatory process as a gating mechanism to gain control over their own spending. This is...